



## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.

1331-138

SERIAL NO.

08/460,186

APPLICANT

Reid W. Von Borstel, et al

FILING DATE

June 2, 1995

GROUP

1200

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
A.K.	5,077,280	12/91	Sommadossi et al			
A.K.	4,874,602	10/89	Calabresi et al			
A.K.	4,950,466	8/90	Calabresi et al			
A.K.	4,757,139	7/88	Kawaguchi et al			

## FOREIGN PATENT DOCUMENTS

						TRANSLATION	
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO
A.K.	WO 91/16315	10/91	PCT				
	WO 89/09603	10/89	PCT				
	WO 90/09163	8/90	PCT				
	WO 90/08550	8/90	PCT				
	0 056 265	7/82	European Patent Appln.				
	1 473 148	5/77	United Kingdom				
	1 297 398	11/72	Great Britain				
	60-174797	2/84	Japan (Abstract)				
	WO 89/03837	5/89	PCT				
	WO 89/03838	5/89	PCT				

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, etc.)

A.K.	-	D.S. Martin et al, "Cancer Res.", 42, 3964-3970, 1982, "High-Dose 5-Fluorouracil with Delayed Uridine 'Rescue' in Mice."
	-	D.S. Martin et al., "Cancer Res.", 43, 4653, 1983, "Improved Therapeutic Index with Sequential N-Phosphonacetyl-L-aspartate plus High-Dose Methotrexate plus High-Dose 5-Fluorouracil and Appropriate Rescue."
	-	Proceedings of AACR, 28, 195, March 1987 - No. 775 - "Phase I Clinical and Pharmacokinetics Study of Orally Administered Uridine."
	-	C.J. van Groeningen et al, Cancer Treatment Reports, Vol. 70, No. 6, 745, June 1986, "Clinical and Pharmacokinetic Studies of Prolonged Administration of High-Dose Uridine Intended for Rescue from 5-FU Toxicity."
	-	N.I. Belyanchikova et al, Byulleten 'Eksperimental' noi Biologii i Meditsiny, Vol. 91, No. 1, p67-69, "Particular Features of Hematopoiesis in Mice Protected by Deoxycytidine Against the Lethal Effect of Cytosar." (1981) /ESO/
	-	K. Bhalla et al, Blood, Vol. 70, No. 2, August 1987, pp 568-571, "Deoxycytidine Preferentially Protects Normal Versus Leukemic Myeloid Progenitor Cells from Cytosine Arabinoside-Mediated Cytotoxicity."
	-	S. Grant et al, Leukemia Research, M.S. 045, Pergamon Journals Ltd., "Interaction of Deoxycytidine and Deoxycytidine Analogs in Normal and Leukemic Human Myeloid Progenitor Cells." (1986) vol.10 no.9 pp.1139-46
	-	K. Bhalla et al, Leukemia, Vol. 2 (10) 709-10, 1988, "Phase I Clinical and Pharmacologic Study of Deoxycytidine." /ESO/

Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ATTY. DOCKET NO.

SERIAL NO.

1331-138

08/460,186

## INFORMATION DISCLOSURE CITATION

APPLICANT

Reid W. Von Borstel, et al

(Use several sheets if necessary)

FILING DATE

June 2, 1995

GROUP

1803 / 20 0

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

TRANSLATION

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, etc.)

		- J. Sommadossi et al, <u>Timicrobial Agents and Chemotherapy</u> , Vol. 32, No. 7, p. 997-1001, July 1988, "Uridine Reverses the Toxicity of 3'-Azido-3'-Deoxythymidine in Normal Human Granulocyte-Macrophage Progenitor Cells In Vitro without Impairment of Antiretroviral Activity."
o	AJK	- A. Falcone et al, <u>Blood</u> , Vol. 76, No. 11, pp 2216-2221, (December 1, 1990), "Differential Effects of Benzylacyclouridine on the Toxic and Therapeutic Effects of Azidothymidine in Mice."
		- K. Bhalla et al, <u>Blood</u> , Vol. 74, No. 6, pp 1923-1928 (November 1, 1989), "2'-Deoxycytidine Protects Normal Human Bone Marrow Progenitor Cells In Vitro Against the Cytotoxicity of 3'-Azido-3'-Deoxythymidine with Preservation of Antiretroviral Activity."
		- Z. M. Gomez et al, <u>Antimicrobial Agents and Chemotherapy</u> , Vol. 34, No. 7, p. 1371-1375, July 1990, "Antimalarial Activity of a Combination of 5-Fluorouracil and Uridine in Mice."
		<del>Oligonucleotide Products, Sigma Catalog, pp. 1726-1728</del>
		- M. Iigo et al, <u>Biochemical Pharmacology</u> , Vol. 39, No. 7, 1247 (1990), "Differential Effects of 2,2'-Anhydro-5-Ethyluridine, A Uridine Phosphorylase Inhibitor, on the Antitumor Activity of 5-Fluorouridine and 5-Fluoro-2'-Deoxyuridine."
o		- P. Calabresi et al, <u>Blood</u> , Vol. 76, No. 11, pp 2210-2215 (December 1990), "Benzylacyclouridine Reverses Azidothymidine-Induced Marrow Suppression Without Impairment of Anti-Human Immunodeficiency Virus Activity."
		- W.D. Ensminger et al, <u>Biochemical Pharmacology</u> , Vol. 28, p. 1541-1545 (1979), "Thymidine 5'-O-Pivaloate, A Prodrug Derivative of Thymidine with Potential Applications in High-Dose Methotrexate Therapy."
		- Martin et al, <u>Journal of Pharmaceutical Sciences</u> , Vol. 76, No. 2, pp 180-183, issued February 1987, "Synthesis and Antiviral Activity of Various Esters of 9-[(1,3-Dihydroxy-2-propoxy)methyl]guanine."
		- Casida et al, <u>Biochemical Pharmacology</u> , Vol. 15, pp 627-644, issued 1966, "3',5'-Diastereomers of 5-Fluoro-2'-Deoxyuridine and Thymidine Hydrolysis by Esterases in Human, Mouse, and Insect Tissue."
		- Losse et al, <u>Chemical Abstracts</u> , Vol. 118, issued 1993, "A convenient pathway to 2'-(tert-butyloxycarbonyl)-ribonucleosides," p. 884, col. 1, abstr. no. 60026c, J. Prakt. Chem./Chem.-Ztg., 334(6), 531-532

Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-FB-A820 (also PTO-1449)